The local medical sector is abuzz with the introduction of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing impressive results in early trials for treating obesity. This therapy offers https://bookmarkcitizen.com/story21747916/retatrutide-australia-a-new-prospect-for-weight-management